A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers
Completed
Novartis
Phase 4
2004-08-01
The objective of this trial was to confirm the tolerability of prednisolone acetate 0.5% eye
drops by testing the hypothesis that the ocular safety and tolerability of prednisolone
acetate 0.5% eye drops are equivalent to vehicle. Thus healthy volunteers have been selected
and have been treated by using a crossover design.
A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
Completed
Novartis
Phase 4
2004-08-17
The primary objective was to demonstrate that two days of treatment with 0.5% prednisolone
acetate eye-drops after cataract surgery are superior to vehicle in reducing the flare in the
anterior chamber of the operated eye.
A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
Completed
Bausch & Lomb Incorporated
Phase 3
2005-07-01
The purpose of this study is to demonstrate the bioequivalence of the combination test agent,
prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension compared to PredForte
(prednisolone acetate 1.0%) ophthalmic suspension. Bioequivalence will be measured by
comparing aqueous humor concentrations of prednisolone acetate.
Prospective randomized clinical trial comparing Laser Alone v. Laser and posterior sub-tenon
injection of triamcinolone acetonide for primary and refractory clinically significant
macular edema.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
